Trailing-twelve-month (TTM) revenue is $13.60 Billion with a year-over-year growth of +6.49%. Revenue represents the total income generated from the company's primary business operations.
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q3 FY2025Period ended 2025-09-27 | $3,339,000,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-11-04 |
| Q4 FY2025Period ended 2025-12-27 | $3,437,000,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-02-24 |
| Q1 FY2026Period ended 2026-03-28 | $3,368,000,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-05-05 |
| Q2 FY2026Period ended 2026-06-27 | $3,458,000,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-08-04 |
| TTM revenue | $13,602,000,000 |
Current P/S: $9,705,728,400 market capitalization ÷ $13,602,000,000 TTM revenue = 0.71x.
Market capitalization source: FMP quote. Quote observed 2026-09-21T20:00:01.000Z. Latest revenue period ended 2026-06-27.
Current market capitalization comes from the quote provider. EPS weighted-average shares are a separate measure.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
Reported quarterly revenue; no daily interpolation. Q2 FY2026 (2026-06-27): $3.46B.
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters Quote observation: 2026-09-22T11:55:36.201Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-09-11.
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2018-12-29 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
2025-12-27 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
FMP selected disclosures by reporting period. Rows match exact source labels; they may overlap. N/A means no matching disclosure, not zero. Filing links identify reviewed presentation labels for that period.
| FMP source label (unverified unless linked) | FY20122012-12-29 · USD | FY20132013-12-28 · USD | FY20142014-12-27 · USD | FY20152015-12-26 · USD | FY20162016-12-31 · USD | FY20182018-12-29 · USD |
|---|---|---|---|---|---|---|
| Healthcare Distribution | $8.7B | $9.2B | $10.0B | $10.3B | $11.1B | $12.7B |
| Technology | $283M | $320M | $349M |
FMP selected disclosures by reporting period. Rows match exact source labels; they may overlap. N/A means no matching disclosure, not zero. Filing links identify reviewed presentation labels for that period.
| FMP source label (unverified unless linked) | FY20132013-12-28 · USD | FY20142014-12-27 · USD | FY20152015-12-26 · USD | FY20162016-12-31 · USD | FY20182018-12-29 · USD | FY20252025-12-27 · USD |
|---|---|---|---|---|---|---|
| International | $3.7B | $4.1B | $3.8B | $4.0B | $4.9B | N/A |
| UNITED STATES | $5.8B | $6.2B | $6.8B |
$13.60B
$13.60 Billion
+6.49%
vs. $12.77B a year ago (TTM)
+2.71%
5 Year compound annual growth rate
1 Year
+6.49%
3 Year
+2.57%
5 Year
+2.71%
10 Year
+2.20%
15 Year
+3.60%
20 Year
+5.31%
CAGR shows the annualized growth rate over the specified period, smoothing out year-to-year volatility.
| Year | Revenue | YoY Change | % Change |
|---|---|---|---|
| 2025 | $13.18B | +$511.00M | +4.03% |
| 2024 | $12.67B | +$334.00M | +2.71% |
| 2023 | $12.34B | ($308.00M) | (2.44%) |
| 2022 | $12.65B | +$246.00M | +1.98% |
| 2021 | $12.40B | +$2.28B | +22.55% |
| 2020 |
TTM Growth
+6.49%
3-Year CAGR
+2.57%
5-Year CAGR
+2.71%
Revenue growth vs the same fiscal quarter in the prior fiscal year, last 40 comparable quarters.
Current FMP quote-based enterprise value / four-quarter revenue Quote observation: 2026-09-22T11:55:36.201Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-09-11.
| $426M |
| $509M |
| $8.3B |
| $9.1B |
| $10.12B |
| +$133.34M |
| +1.34% |
| 2019 | $9.99B | ($3.22B) | (24.36%) |
| 2018 | $13.20B | +$740.45M | +5.94% |
| 2017 | $12.46B | +$889.88M | +7.69% |
| 2016 | $11.57B | +$941.95M | +8.86% |
